{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:41:59Z","timestamp":1761093719868,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4002,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,2]]},"abstract":"<jats:p>A 27\u2010year\u2010old man was admitted with tremulousness, diaphoresis, tachypnea (28 breaths\/min), full\u2010body rigidity, irritability, paranoia, and auditory and visual hallucinations 2 days after stopping long\u2010term \u03b3\u2010hydroxybutyrate (GHB) and 8 hours after stopping alcohol intake. He received intravenous fluids and tapering dosages of lorazepam to control agitation and rigidity, and recovered with no significant sequelae after 8 days. Abrupt cessation of GHB after high\u2010dosage abuse can precipitate a clinically significant withdrawal syndrome. Lorazepam should be considered for treatment of GHB withdrawal. Concomitant alcohol abuse may mask early GHB withdrawal symptoms and exacerbate withdrawal.<\/jats:p>","DOI":"10.1592\/phco.21.2.254.34110","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T05:03:57Z","timestamp":1086584637000},"page":"254-257","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Successful Management of Prolonged \u03b3\u2010Hydroxybutyrate and Alcohol Withdrawal"],"prefix":"10.1002","volume":"21","author":[{"given":"Toya M.","family":"Bowles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger W.","family":"Sommi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(91)90050-T"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04049.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/33.5.465"},{"key":"e_1_2_1_5_2","first-page":"861","article-title":"Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate","volume":"39","author":"Centers for Disease Control","year":"1990","journal-title":"MMWR"},{"issue":"3","key":"e_1_2_1_6_2","first-page":"519","article-title":"Drugs used in acquaintance rape","volume":"39","author":"Smith K.M.","year":"1999","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_1_7_2","unstructured":"U.S. Food and Drug AdministrationStatement by Jane E Henney M.D. before the Committee on Health Education Labor and Pensions. United States Senate hearing on e\u2010drugs March 21 2000."},{"issue":"7","key":"e_1_2_1_8_2","first-page":"354","article-title":"Acute poisoning from gamma hydroxybutyrate (GHB)","volume":"92","author":"Steele M.T.","year":"1995","journal-title":"MO Med"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(99)00163-8"},{"key":"e_1_2_1_10_2","first-page":"553","article-title":"Gamma hydroxybutyrate withdrawal","volume":"35","author":"Dyer J.E.","year":"1997","journal-title":"J Toxicol Clin Toxicol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.2.469"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb03640.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00952999809001706"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563659709001236"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00687-3"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.171.3969.404"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(95)00057-Q"},{"issue":"5","key":"e_1_2_1_18_2","first-page":"650","article-title":"Benzodiazepine use for alcohol withdrawal","volume":"160","author":"Holbrook A.M.","year":"1999","journal-title":"Can Med Assoc J"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1994.tb03743.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.2.254.34110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.2.254.34110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:24:44Z","timestamp":1761049484000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.2.254.34110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["10.1592\/phco.21.2.254.34110"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.2.254.34110","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}